

# INFINITY BIO

THE ANTIBODY REACTOME COMPANY

## ABOUT THE ANTIBODY REACTOME

Antibodies play a critical role in the immune response. Full characterization of the antibody reactome, all possible binding interactions between antibodies and target molecules, offers a comprehensive view of the immune system's prior and ongoing responses to infections, microbes, allergens, insect vectors of disease, self-proteins (autoimmunity and cancer), vaccines, and therapeutics. Integration of antibody reactome data with other types of omics data, such as genomics, metabolomics and proteomics, can generate critical insights into health outcomes.

Infinity Bio, Inc. provides detailed insights into the immune system with its proprietary antibody reactome profiling platform: Molecular Indexing of Proteins by Self-Assembly (MIPSA). MIPSA libraries encompass comprehensive and unbiased panels of pathogens, the human proteome, and the allergome, revealing the targets of past and ongoing immune responses. Developed at Johns Hopkins University in The Laboratory of Precision Immunology, MIPSA builds on decades of work in genomics, proteomics, immunology, and bioinformatics. Infinity Bio's assays are engineered to enable best-in-class quality, data accuracy, turnaround times and cost-efficiency.

## ABOUT THE EARLY ACCESS GRANT PROGRAM

To enhance the research community's access to and understanding of antibody reactome data, Infinity Bio is launching an early access grant program.

The program is intended to generate valuable antibody reactome datasets in the following focus areas:


1. Neurodegenerative disorders
2. Autoimmune disorders
3. Oncology
4. Infectious Diseases

Infinity Bio will award up to:

**Four (4) research grants, each valued at (up to) \$88,000 USD**

The grants will provide analytical services including sample processing and bioinformatic data analysis for up to 176 samples analyzed with up to three of the following antigen libraries:

- VirSIGHT™: a library with 285,000+ unique peptides covering all known human viruses for a comprehensive assessment of immune responses to past and ongoing infections, as well as vaccines.



- HuSIGHT™: a library with 16,000+ full-length human proteins, 353,000+ unique peptides, and 880 full-length secreted mature proteins covering all human open reading frames for comprehensive detection of auto-reactivities against self-proteins (autoimmune or cancer responses).
- EnviroSIGHT™: a library with 242,000+ unique peptides covering all known protein allergens (food and environmental including insects), non-viral pathogens, and immune-reactive gut microbes (both IgG and IgE analyses are available).
- MuSIGHT™: a library with 273,000+ peptides covering all mouse open reading frames (> 26,000) for comprehensive detection of auto-reactivities against self-proteins (autoimmune or cancer responses) in pre-clinical models of human disease.


Samples can include serum, plasma, and/or cerebrospinal fluid. A sample is defined by a single antibody isotype pull-down. Multiple isotypes can be analyzed from the same sample (e.g. IgG, IgA, IgM or IgE), but each antibody isotype pull-down is treated as a separate sample.

## HOW TO APPLY

- Applicants shall propose a study of up to 176 samples to address an important biomedical question. The study design may be hypothesis generating, hypothesis testing, or a pilot for a much larger study.
- Please include a description of other data sets that exist for the same samples (e.g. other omics data, detailed phenotypic information, etc.)
- Please provide references to publications that involved the samples proposed in the study design.
- The proposal should not be longer than 2 pages.
- Preliminary data will be considered but is not required.
- To be considered, the applicants shall submit their proposal by August 1<sup>st</sup>, 2025, through the website at [www.infinitybio.com](http://www.infinitybio.com).

## GRANT PROGRAM RULES


- There is a limit of one entry per investigative team. Investigators from any country are eligible.
- All submitted materials must be in English.
- The applicant is responsible for ensuring that all necessary and legally required informed consents, authorizations, approvals, and permissions have been obtained to participate in this program including any required Internal Review Board (IRB) approvals.
- The applicant is responsible for sample shipping costs.
- Samples must be immediately available for shipment to Baltimore, MD, United States (prospective collection studies will not be considered, samples must be cleared for shipment to USA).
- The applicant agrees that the project will be completed (data generated and analyzed) within 6 months of the date of the antibody reactome data return.
- Applicants must agree to Infinity Bio services terms and conditions.




- Winners must agree to allow Infinity Bio to officially announce the name of the investigative group, the project name or area of research, and the institution or company.
- Infinity Bio will keep confidential all abstracts, applicant names and institutions, and all information submitted in the program applications.
- All decisions of the selection committee are final.
- The winner agrees to provide a written progress report on the project to Infinity Bio 6 months after receipt of the award.
- Applicants agree to comply with the Additional Grant Programs Terms and Conditions. (See below)

## ADDITIONAL GRANT PROGRAM TERMS & CONDITIONS

- The applicant agrees that they have read, understood, and agree to the Infinity Bio Grant Program Rules and by these Additional Terms and Conditions.
- By applying, the applicant represents and warrants that:
  - They have obtained all required authorizations and permissions from their institution or company and written informed consent.
  - They will not violate any of their institution's or company's rules, policies, or procedures by applying to this Grant Program.
- Infinity Bio is not responsible for the applicant's actions or decisions or those of their employees or agents.
- Infinity Bio reserves the right to discontinue or modify the Grant Program at any time and for any reason.
- Infinity Bio may refuse to award the prize to any or all applicants if Infinity Bio determines at its sole discretion that the granting of such award would result in a violation of an applicable federal, state, or local law, rule, or policy.
- The successful applicant will own any intellectual property arising from the results that are free of any encumbrances and may take such steps as it may decide from time to time, and at its own expense, to register and maintain any protection for that intellectual property, including filing and prosecuting patent applications for any of the results.
- The winner and their employees and agents hereby irrevocably authorize Infinity Bio to copy, exhibit, publish, and distribute images, audio, video, and other works based upon the submission, oral discussions, and presentations, solely for Infinity Bio marketing purposes. Applicant hereby releases and holds harmless Infinity Bio and forever discharges Infinity Bio from all claims, demands, and causes of action which may arise by reason of this authorization.
- Except for the services rendered by Infinity Bio, each applicant is responsible for all of their own costs, and the costs of its employees and agents, that are incurred or that may be incurred in connection with this Grant Program, including, without limitation, any tax liability and any costs associated with entering into and participating in this Grant Program, developing ideas and materials, submitting materials, traveling and generally participating in the Grant Program.
- The applicant understands and agrees that no ideas, information, or materials that are submitted to or otherwise provided to Infinity Bio in connection with this Grant Program will be returned.



- Each applicant and their employees and agents agree to accept and abide by the Grant Program Rules and agrees that any dispute about the conduct of the Grant Program, rule interpretation or the award of the prizes, shall be resolved by Infinity Bio, whose decision shall be binding and final. By participating, each applicant and their employees and agents agree to release and hold harmless Infinity Bio and all of its officers, directors, employees, agents and representatives, from any injury, loss or damage, including death or property damage, due in-whole or in-part, directly or indirectly to the acceptance, use, or misuse of a grant, participation in any Grant Program-related activity, or participation in the Grant Program. Infinity Bio is not responsible for any typographical or other error herein, administration of the Grant Program or in the announcement of the award, including such error as may give an erroneous indication that an award has been won.
- IN NO EVENT SHALL INFINITY BIO, ITS OFFICERS, DIRECTORS, EMPLOYEES, OR AGENTS, OR THOSE OF ITS AFFILIATES BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES WHATSOEVER ARISING UNDER OR AS A RESULT OF ENTRANCE IN OR PARTICIPATION IN THE GRANT PROGRAM, WHETHER BASED ON WARRANTY, CONTRACT, TORT, STRICT LIABILITY, OR ANY OTHER LEGAL THEORY, AND WHETHER OR NOT INFINITY BIO IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, THE FOREGOING LIMITATION OF LIABILITY SHALL APPLY TO THE FULLEST EXTENT PERMITTED BY LAW. THE TOTAL LIABILITY OF INFINITY BIO ARISING UNDER OR RELATING TO THIS GRANT PROGRAM SHALL NOT EXCEED THE TOTAL VALUE OF THE PRIZE AWARDED TO THE SUCCESSFUL APPLICANT UNDER THIS GRANT PROGRAM.



For any further questions, please contact  
JP Laine, VP of BD/Sales:  
[jp.laine@infinitybio.com](mailto:jp.laine@infinitybio.com)